In these cancers, pemigatinib has shown an ability to substantially inhibit tumor progression and induce partial responses, thereby extending survival in a subset of patients who have limited treatment options.13 The implications of these findings for GB, especially for the uncommon cases involving FGFR3 fusion genes, are intriguing. Here, FGFR3 is linked to neoplasm.